Risk factors

Kiora Pharmaceuticals (KPRX) risk factors

Item 1A of every Kiora Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open KPRX in Gloom →
Kiora Pharmaceuticals' chart, financials and news, free in your browser.Open KPRX in Gloom →
  • FY2025 10-K risk factors
    52 risks3 new5 dropped8 reworded

    TOI’s control over KIO-301 development and commercialization is a central risk, including possible discontinuation or narrower indications.

    Filed Mar 25, 2026
  • FY2024 10-K risk factors
    54 risks

    Kiora Pharmaceuticals faces intense clinical, regulatory, and financial risks centered on its lead product candidates KIO-104 and KIO-301. The company has a history of substantial operating losses and requires additional capital to fund operations into 2027. Reliance on third-party collaborators like TOI and third-party manufacturers creates significant operational vulnerabilities.

    Filed Mar 25, 2025